Bullous Pemphigoid: Clinical Practice Guidelines

被引：27

作者：

de Vega, I. Fuertes ^{[1
]}

Iranzo-Fernandez, P. ^{[2
]}

Mascaro-Galy, J. M. ^{[2
]}

机构：

[1] Univ Autonoma Barcelona, Hosp Parc Tauli Sabadell, Serv Dermatol, Sabadell, Spain

[2] Univ Barcelona, Hosp Clin, Serv Dermatol, Barcelona, Spain

来源：

ACTAS DERMO-SIFILIOGRAFICAS | 2014年 / 105卷 / 04期

关键词：

Autoimmune blistering diseases; Bullous pemphigoid; Subepidermal blister; Treatment and management guidelines; Immunosuppressive agents;

D O I：

10.1016/j.ad.2012.10.022

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease in which auto antibodies are directed against components of the basement membrane. Most of these antibodies belong to the immunoglobulin G class and bind principally to 2 hemidesmosomal proteins: the 180-kD antigen (BP180) and the 230-kD antigen (BP230). It is the most common blistering disease in the adult population in developed countries, with an estimated incidence in Spain of 0.2 to 3 cases per 100,000 inhabitants per year. The disease primarily affects older people, although it can also occur in young people and even in children. In recent years, advances in clinical practice have led to a better understanding and improved management of this

引用

页码：328 / 346

页数：19

共 47 条

[1] Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment [J].

Ahmed, AR .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (06) :825-835

[2]

APPELHANS M, 1993, HAUTARZT, V44, P143

[3] A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid [J].

Beissert, Stefan ;

Werfel, Thomas ;

Frieling, Uta ;

Boehm, Markus ;

Sticherling, Michael ;

Stadler, Rudolf ;

Zillikens, Detlef ;

Rzany, Berthold ;

Hunzelmann, Nicolas ;

Meurer, Michael ;

Gollnick, Harald ;

Ruzicka, Thomas ;

Pillekhamp, Hans ;

Junghans, Volker ;

Bonsmann, Gisela ;

Luger, Thomas A. .

ARCHIVES OF DERMATOLOGY, 2007, 143 (12) :1536-1542

[4] Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases [J].

Bouscarat, F ;

Chosidow, O ;

PicardDahan, C ;

Sakiz, V ;

Crickx, B ;

Prost, C ;

Roujeau, JC ;

Revuz, J ;

Belaich, S .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (04) :683-684

[5] AZATHIOPRINE PLUS PREDNISONE IN TREATMENT OF PEMPHIGOID [J].

BURTON, JL ;

HARMAN, RRM ;

PEACHEY, RDG ;

WARIN, RP .

BRITISH MEDICAL JOURNAL, 1978, 2 (6146) :1190-1191

[6] Evidence-Based Management of Bullous Pemphigoid [J].

Daniel, Benjamin S. ;

Borradori, Luca ;

Hall, Russell P., III ;

Murrell, Dedee F. .

DERMATOLOGIC CLINICS, 2011, 29 (04) :613-+

[7] Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: Aan open prospective study of 18 cases [J].

Dereure, O ;

Bessis, D .

ARCHIVES OF DERMATOLOGY, 2002, 138 (09) :1255-1256

[8]

Di Zenzo Giovanni, 2007, Adv Dermatol, V23, P257, DOI 10.1016/j.yadr.2007.07.013

[9] DIRECT IMMUNOFLUORESCENCE MICROSCOPY OF 1 MOL/L SODIUM CHLORIDE-TREATED PATIENT SKIN [J].

DOMLOGEHULTSCH, N ;

BISALBUTRA, P ;

GAMMON, WR ;

YANCEY, KB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (06) :946-951

[10] A pathogenic role for IgE in autoimmunity: Bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice [J].

Fairley, Janet A. ;

Burnett, Christopher T. ;

Fu, Chang-Ling ;

Larson, David L. ;

Fleming, Matthew G. ;

Giudice, George J. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (11) :2605-2611

← 1 2 3 4 5 →